BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 14603341)

  • 21. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
    Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
    J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
    Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary tonsillar lymphomas according to the new World Health Organization classification: to report 87 cases and literature review and analysis.
    Mohammadianpanah M; Daneshbod Y; Ramzi M; Hamidizadeh N; Dehghani SJ; Bidouei F; Khademi B; Ahmadloo N; Ansari M; Omidvari S; Mosalaei A; Dehghani M
    Ann Hematol; 2010 Oct; 89(10):993-1001. PubMed ID: 20440503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.
    Le Gouill S; Talmant P; Touzeau C; Moreau A; Garand R; Juge-Morineau N; Gaillard F; Gastinne T; Milpied N; Moreau P; Harousseau JL; Avet-Loiseau H
    Haematologica; 2007 Oct; 92(10):1335-42. PubMed ID: 18024371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation.
    Costa LJ; Feldman AL; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Ansell SM
    Br J Haematol; 2008 Jul; 142(3):404-12. PubMed ID: 18492096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor.
    Engelhard M; Brittinger G; Huhn D; Gerhartz HH; Meusers P; Siegert W; Thiel E; Wilmanns W; Aydemir U; Bierwolf S; Griesser H; Tiemann M; Lennert K
    Blood; 1997 Apr; 89(7):2291-7. PubMed ID: 9116271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.
    Hernandez-Ilizaliturri FJ; Deeb G; Zinzani PL; Pileri SA; Malik F; Macon WR; Goy A; Witzig TE; Czuczman MS
    Cancer; 2011 Nov; 117(22):5058-66. PubMed ID: 21495023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors predicting long-term survival in low-risk diffuse large B-cell lymphoma.
    Møller MB; Pedersen NT; Christensen BE
    Am J Hematol; 2003 Oct; 74(2):94-8. PubMed ID: 14508794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy.
    Song MK; Chung JS; Sung-Yong O; Lee GW; Kim SG; Seol YM; Shin HJ; Choi YJ; Cho GJ; Shin DH; Yun EY
    Ann Hematol; 2010 Oct; 89(10):985-91. PubMed ID: 20428871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas.
    Jardin F; Ruminy P; Kerckaert JP; Parmentier F; Picquenot JM; Quief S; Villenet C; Buchonnet G; Tosi M; Frebourg T; Bastard C; Tilly H
    Haematologica; 2008 Apr; 93(4):543-50. PubMed ID: 18287131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas.
    Muris JJ; Meijer CJ; Cillessen SA; Vos W; Kummer JA; Bladergroen BA; Bogman MJ; MacKenzie MA; Jiwa NM; Siegenbeek van Heukelom LH; Ossenkoppele GJ; Oudejans JJ
    Leukemia; 2004 Mar; 18(3):589-96. PubMed ID: 14712286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasmablastic lymphoma and related disorders.
    Hsi ED; Lorsbach RB; Fend F; Dogan A
    Am J Clin Pathol; 2011 Aug; 136(2):183-94. PubMed ID: 21757592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of molecular staging by PCR-amplification of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma (DLBCL).
    Mitterbauer-Hohendanner G; Mannhalter C; Winkler K; Mitterbauer M; Skrabs C; Chott A; Simonitsch-Klupp I; Gleiss A; Lechner K; Jaeger U
    Leukemia; 2004 Jun; 18(6):1102-7. PubMed ID: 15085149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diffuse large B-cell lymphoma of bone: an analysis of differentiation-associated antigens with clinical correlation.
    de Leval L; Braaten KM; Ancukiewicz M; Kiggundu E; Delaney T; Mankin HJ; Harris NL
    Am J Surg Pathol; 2003 Sep; 27(9):1269-77. PubMed ID: 12960812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasmablastic transformation of low-grade B-cell lymphomas: report on 6 cases.
    Martinez D; Valera A; Perez NS; Sua Villegas LF; Gonzalez-Farre B; Sole C; Gine E; Lopez-Guillermo A; Roue G; Martinez S; Sant F; Warzocha K; Robak T; Czader M; Villamor N; Colomo L; Campo E; Martinez A
    Am J Surg Pathol; 2013 Feb; 37(2):272-81. PubMed ID: 23282972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis.
    Bouabdallah R; Mounier N; Guettier C; Molina T; Ribrag V; Thieblemont C; Sonet A; Delmer A; Belhadj K; Gaulard P; Gisselbrecht C; Xerri L
    J Clin Oncol; 2003 Apr; 21(7):1271-7. PubMed ID: 12663714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Diffuse large B-cell lymphoma with expression of anaplastic lymphoma kinase protein: clinicopathologic and immunohistochemical study of 5 cases].
    Wang WY; Ma ZG; Li GD; Liu WP; Zhong L; Wang Y; Li JM; Li L; Jiang W; Tang Y; Liao DY
    Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):529-34. PubMed ID: 17134546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extranodal and nodal diffuse large B cell lymphoma of the head and neck: two different entities?
    Sánchez LA; Redondo AM; Muñez OB; Sebastián E; Alcoceba M; González M; Martín A; Caballero D
    Ann Hematol; 2015 Apr; 94(4):609-16. PubMed ID: 25537456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.